Drug Profile
Recombinant human interferon alpha-2b biosimilar - Tianjin Sinobioway Biomedicine
Alternative Names: Alfaron; Jaferon; rhIFNα2bLatest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator Tianjin Sinobioway Biomedicine
- Developer Beijing Ditan Hospital Capital Medical University; Tianjin Sinobioway Biomedicine
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Condylomata acuminata; Hepatitis A; Hepatitis B; Herpes genitalis; Leukaemia
- No development reported Coxsackievirus infections
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for phase-I development in Coxsackievirus-infections(In children, In infants) in China (Topical, Spray)
- 07 Nov 2017 Launched for Condylomata acuminata in China (Topical) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)
- 07 Nov 2017 Launched for Hepatitis A in China (Injection) before November 2017 (Tianjin Sinobioway Biomedicine website, November 2017)